News Releases News Releases Year None202120202019201820172016 Jun 11, 2021 Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting Jun 11, 2021 Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma Jun 04, 2021 Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers Jun 04, 2021 Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision To Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly To Patients Jun 02, 2021 Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise Jun 02, 2021 Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests May 20, 2021 Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome May 19, 2021 Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device Apr 27, 2021 Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma Apr 20, 2021 Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Next page next › Last page last » Tools Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
News Releases Year None202120202019201820172016 Jun 11, 2021 Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting Jun 11, 2021 Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma Jun 04, 2021 Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers Jun 04, 2021 Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision To Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly To Patients Jun 02, 2021 Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise Jun 02, 2021 Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests May 20, 2021 Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome May 19, 2021 Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device Apr 27, 2021 Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma Apr 20, 2021 Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Next page next › Last page last »
Jun 11, 2021 Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Jun 11, 2021 Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
Jun 04, 2021 Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
Jun 04, 2021 Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision To Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly To Patients
Jun 02, 2021 Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
Jun 02, 2021 Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests
May 20, 2021 Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
May 19, 2021 Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device
Apr 27, 2021 Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
Apr 20, 2021 Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
